資源描述：
《卵巢癌中MDR1的表達(dá)及其臨床意義》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫(kù)。
1、卵巢癌中MDR1的表達(dá)及其臨床意義作者：梁川，吳緒峰,陳慧君單位：武漢大學(xué)中南醫(yī)院婦瘤科【摘要】目的檢測(cè)MDR1在卵巢癌中的表達(dá)并探討其在卵巢癌化療耐藥中的作用。方法采用RTPCR復(fù)合定量技術(shù)対40例卵巢癌、20例良性卵巢腫瘤、20例止常卵巢組織中MDR1的表達(dá)進(jìn)行檢測(cè)，分析其表達(dá)與臨床病理特征及化療療效的相關(guān)性。結(jié)果卵巢癌中MDR1的表達(dá)顯著高于正常組及良性腫瘤組，且腫瘤分化程度越差其表達(dá)越高，P<0.05。MDR1在術(shù)前化療組屮的陽(yáng)性表達(dá)率就著高于術(shù)前未化療組，P<0.05oMDRI陰性組患者的化療反應(yīng)率顯著高于陽(yáng)性組患者(70.
2、6%比43.5%),P<0.05,MDR1陰性對(duì)化療有效的預(yù)測(cè)值為70.6%o結(jié)論MDRInJ能在卵巢癌獲得性耐藥的形成中發(fā)揮一定作用，MDR1的檢測(cè)可能有助于卵巢癌化療方案的制定，并成為預(yù)測(cè)化療療效的有用指標(biāo)?！娟P(guān)鍵詞】卵巢癌；多藥耐藥基因；逆轉(zhuǎn)錄聚合酶鏈反應(yīng)ExpressionofMultidrugResistanceGeneinEpithelialOvarianCarcinomaandItsClinicalSignificanceLIANGChuan,WUXufeng,CHENHuijunGynecologicOncologyDepartm
3、entofZhongnanHospital,WuhanUniversity,Wuhan430071,ChinaCorrespondingAuthor:WuXufeng,Email：wuxufeng@371.netAbstract：ObjectiveTodetecttheexpressionofmultidrugresistancegene(MDRI)intheepithelialovariancarcinoma,andinvestigateitsroleindrugresistance.MethodsTheexpressionofMDRIin40
4、casesofovariancarcinoma,20casesofbenignovariantumorand20casesofnormalcontrolweredeterminedbyRTPCRtechnique.TherelationsbetweenMDRIexpressionandtheclinicalpathologicalcharacteristicsaswellaschemotherapeuticresponsewerediscussecl.ResultsThepositiveexpressionrateofMDRIinovarianc
5、arcinomawassignificantlyhigherthanthatinbenigntumorsandnormaltissues,andasignificantrelationshipwasshownbetweenitsexpressionandpathologicdifferentiation,P<0.05?TheMDRIpositiveexpressionrateincasesreceivedchemotherapybeforesurgeryweresignificantlyhigherthanincaseswhodidn't,
6、P<0.05?TheresponserateintheMDRInegativegroupwashigherthanthatinthepositivegroup(70.6%vs43.5%),P<0.05.ThepredictivevalueofnegativeMDRIstainingforobjectiveresponsewas70.6%.ConclusionThesedatasuggestedthatMDRImayplayanimportantroleintheacquiredmultidrugresistanceofovarianc
7、arcinoma.DeteiminationofMDRIexpressionmaybeusefulforworkingoutchemotherapyplanandpredictingchemotherapeuticresponseofovariancarcinomapatients.Keywords：Ovariancarcinoma;Multidrugresistancegene;Reversetranscriptionpolymerasechainreaction雖然卵巢癌對(duì)化療相對(duì)敏感，但其遠(yuǎn)期效果并不理想，據(jù)報(bào)道盡管卵巢癌首次化療有效率高達(dá)
8、76%,但復(fù)發(fā)后降至20%[1],藥物耐受是化療失敗的重要原因。腫瘤耐藥的產(chǎn)生是多棊因參與的復(fù)雜過程，其中以多藥耐藥基因MDRI(mul
